Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine added to doxepin for irritable bowel syndrome
IRCT20191106045356N14Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Doxepin + memantine with Doxepin + placebo (2 arms). Primary endpoints: Quality of life score, Pain score and 1 more. Started Dec 2022; status: completed.
02
Drugs
memantinedoxepin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20191106045356N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191106045356N14.